One To Watch
BLEEDnFIRE Therapeutics
Company Overview
A Swiss early-stage biotechnology company targeting a single genetic lever — hepatic Protein S — to restore thrombin generation across multiple rare bleeding disorders with one GalNAc-siRNA program. BLEEDnFIRE Therapeutics launched publicly on May 27, 2026, backed by non-dilutive grants from Innosuisse, Venture Kick, the Gebert Rüf Foundation Innobooster program, and Kickfund. The company's strategic thesis is that coagulation rebalancing through controlled Protein S suppression can address the unmet needs in indications — von Willebrand disease, Glanzmann thrombasthenia, hemophilia A — that have historically required distinct therapeutic approaches. That pan-indication ambition, built on a single siRNA scaffold, is what puts BLEEDnFIRE on the map this early.
Headquarters and Global Presence
BLEEDnFIRE is headquartered in Bern, Switzerland. Translational research is conducted in close collaboration with the University of Bern and Inselspital (Bern University Hospital), giving the company direct access to academic coagulation expertise and clinical infrastructure.
Founding and History
BLEEDnFIRE was co-founded by Landmark BioVentures AG, the Swiss venture-building firm led by Zaki Sellam. The company's formal public launch came in May 2026, supported by a portfolio of non-dilutive grants rather than institutional equity at inception — a deliberate funding approach common in the Swiss innovation ecosystem. No IPO or acquisition events have occurred; BLEEDnFIRE is pre-clinical and in its earliest stage of independent operation.
Therapy Areas and Focus
The company is focused exclusively on rare bleeding disorders, a field defined by significant unmet need despite recent advances in hemophilia A management. Von Willebrand disease — the most common inherited bleeding disorder — still lacks durable subcutaneous treatment options for severe forms. Glanzmann thrombasthenia, a platelet function disorder, has virtually no approved disease-modifying therapy. BLEEDnFIRE's bet is that all three conditions share sufficient coagulopathic common ground to be addressed by correcting the same upstream regulator.
Technology Platforms and Modalities
BLEEDnFIRE builds on the GalNAc-siRNA delivery paradigm — the same class of chemistry that underpins Alnylam's inclisiran and fitusiran — using hepatic targeting to achieve durable knockdown of Protein S with subcutaneous dosing. Protein S is a natural anticoagulant that dampens thrombin generation; controlled suppression tips the balance toward clot formation without requiring factor replacement. The GalNAc conjugate enables highly selective liver uptake, which is critical for avoiding systemic anticoagulation interference. If BnF-001 performs as the mechanism predicts, infrequent subcutaneous dosing — potentially monthly or less — becomes the commercial value proposition.
Key Pipeline and Programs
BnF-001 is BLEEDnFIRE's sole disclosed program and its entire strategic rationale. It is a GalNAc-conjugated siRNA designed to reduce hepatic Protein S expression, thereby restoring thrombin generation in patients whose bleeding pathology stems from platelet or coagulation factor deficiency rather than excess anticoagulation. Indications in development include hemophilia A (where factor VIII activity is absent or reduced), von Willebrand disease (where impaired platelet adhesion and factor VIII stabilization drive bleeding), and Glanzmann thrombasthenia (a platelet aggregation disorder caused by absent GPIIb/IIIa function). BnF-001 is currently advancing toward clinical candidate nomination — meaning IND-enabling preclinical studies are underway or planned, but no Phase I entry date has been disclosed. The pan-indication design, if validated, would give BLEEDnFIRE a single asset addressable across multiple rare disease populations — a structurally attractive proposition for a company at this scale.
Recent Developments
The company's public launch on May 27, 2026 was the founding event of record, accompanied by confirmation of non-dilutive grant funding from four Swiss innovation bodies: Innosuisse, Venture Kick, the Gebert Rüf Foundation Innobooster program, and Kickfund. The Innosuisse grant specifically supports translational research collaboration with the University of Bern and Inselspital. No clinical data readouts, regulatory interactions, or equity fundraising rounds have been announced as of mid-2026. The company is pre-IND, with clinical candidate nomination as the stated near-term milestone.
Key Personnel
Zaki Sellam, PhD, MBA, serves as CEO and co-founder. Sellam is also co-founder of Landmark BioVentures AG, the Swiss venture-building firm through which BLEEDnFIRE was established, bringing commercial development and bioventure structuring experience. Raja Prince-Eladnani serves as Chief Scientific Officer; he holds a concurrent position as senior scientist at the University of Bern, anchoring BLEEDnFIRE's translational research directly to its academic partner institution.
Strategic Partnerships
The company's primary academic partnership is with the University of Bern and Inselspital, structured around the Innosuisse translational research grant. Landmark BioVentures AG remains a co-founding institutional stakeholder. No commercial licensing deals or pharmaceutical co-development agreements have been disclosed at this stage.
FAQ Section
The strategic logic rests on a shared upstream vulnerability: all three targeted conditions — hemophilia A, von Willebrand disease, and Glanzmann thrombasthenia — result in inadequate thrombin generation, regardless of the specific defect causing it. By suppressing Protein S, a natural anticoagulant that limits thrombin output, BnF-001 attempts to compensate for the downstream deficit without correcting the primary genetic lesion. If the approach is validated, one asset becomes commercially addressable across multiple rare disease populations — reducing development risk spread and increasing deal attractiveness to potential partners.
Protein S is a vitamin K-dependent plasma protein that acts as a cofactor for activated Protein C, collectively dampening thrombin generation and limiting clot formation. In healthy individuals this is a protective anticoagulant mechanism; in patients with inherited bleeding disorders, it becomes a counterproductive brake on an already impaired system. Reducing Protein S activity with an siRNA effectively shifts the coagulation balance toward thrombin generation without introducing exogenous clotting factors — a mechanism validated in principle by fitusiran, Sanofi's antithrombin-targeting siRNA, which demonstrated bleed reduction across hemophilia subtypes in Phase III.
The most direct comparator is fitusiran (Alhemo), which targets antithrombin rather than Protein S. BLEEDnFIRE is betting that Protein S is a more selective and potentially safer leverage point in the coagulation cascade. The pan-indication design — explicitly targeting von Willebrand disease and Glanzmann thrombasthenia alongside hemophilia A — is also differentiated; most rebalancing programs have focused primarily on hemophilia. The GalNAc delivery chemistry provides hepatic selectivity and subcutaneous convenience, consistent with the modern siRNA platform standard.
BnF-001 is pre-clinical as of mid-2026, advancing toward clinical candidate nomination — the formal preclinical milestone that precedes IND-enabling studies. No projected Phase I start date or trial registration number has been disclosed. The Innosuisse-funded translational research collaboration with the University of Bern and Inselspital is expected to generate the pharmacology and safety data required for nomination. Given the pre-clinical stage at launch, first-in-human studies are unlikely before 2028 at the earliest.
BLEEDnFIRE is targeting three disorders. Von Willebrand disease is the most prevalent inherited bleeding disorder globally, affecting approximately 1 in 1,000 people, though severe forms requiring active treatment are far rarer. Hemophilia A affects roughly 1 in 5,000 males. Glanzmann thrombasthenia is ultra-rare, with fewer than 1,000 patients diagnosed in the US and EU combined, but represents a condition with effectively no approved disease-modifying systemic therapy. The combined addressable population, weighted toward the hemophilia A opportunity, creates a commercially viable rare disease portfolio from a single drug candidate.
The company launched in May 2026 and is at the earliest pre-clinical stage, with clinical candidate nomination as its next formal milestone. Funding at launch is entirely non-dilutive, comprising grants from Innosuisse, Venture Kick, the Gebert Rüf Foundation Innobooster program, and Kickfund — a structure that preserves equity while providing runway for translational studies. Equity fundraising has not been announced; the company will almost certainly require a Series A or equivalent institutional round to fund IND-enabling studies and Phase I entry.
At this stage, BLEEDnFIRE is almost entirely de-risked by narrative rather than data. The catalysts and risks to monitor are:
- Clinical candidate nomination for BnF-001, which would confirm the preclinical package is sufficient to advance — the nearest binary event.
- In vivo efficacy and safety data in disease-relevant animal models, particularly demonstrating Protein S knockdown translates to measurable hemostatic correction without prothrombotic overshoot.
- First equity fundraising round: size and investor quality will signal external validation of the platform and team.
- Competitive moves from fitusiran (already approved) and any antithrombin or TFPI-targeting programs advancing in similar indications.
- The academic partnership with Bern/Inselspital: publications or conference presentations will be the earliest public evidence that BnF-001's biology holds up outside the founding team's internal data.
Today's issue
| Headless Content Management with Blaze